PPARA and alcoholic fatty liver disease: Qin et al. demonstrated that GH administration via gene therapy (rAAV2/1 vector containing the GH1 gene) reversed the increased hepatic TG in animal models of alcoholic fatty liver disease after 6 weeks of alcohol exposure by reduced hepatic nSREBP-1c protein expression and stimulated hepatic AMPKα and PPARα activity39.